0001493152-21-023490.txt : 20210923 0001493152-21-023490.hdr.sgml : 20210923 20210923161512 ACCESSION NUMBER: 0001493152-21-023490 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210922 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210923 DATE AS OF CHANGE: 20210923 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardion Health Sciences, Inc. CENTRAL INDEX KEY: 0001642375 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474428421 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38861 FILM NUMBER: 211272691 BUSINESS ADDRESS: STREET 1: 15150 AVENUE OF SCIENCE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92128 BUSINESS PHONE: (800) 873-5141 MAIL ADDRESS: STREET 1: 15150 AVENUE OF SCIENCE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92128 FORMER COMPANY: FORMER CONFORMED NAME: Guardion Health Sciences, LLC DATE OF NAME CHANGE: 20150513 8-K 1 form8-k.htm
0001642375 false 0001642375 2021-09-22 2021-09-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 22, 2021

 

GUARDION HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38861   44-4428421

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

2925 Richmond Avenue, Suite 1200

Houston, Texas 77098

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (800) 873-5141

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   GHSI   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.02 Termination of a Material Definitive Agreement.

 

On September 22, 2021, Guardion Health Sciences, Inc. (the “Company”) entered into a Lease Termination Agreement (the “Agreement”) with Cal-Sorrento, Ltd. (“Cal-Sorrento”) pursuant to which, effective as of October 31, 2021 (the “Termination Date”), the Industrial Lease (the “Lease”) originally dated October 24, 2012, as amended, by and between the Company and Cal-Sorrento with respect to leased premises located at 15150 Avenue of Science, Suite 200, San Diego, California 92128, shall terminate. Pursuant to the Agreement and in consideration for the early termination of the Lease, (i) the Company shall forfeit the security deposit paid to Cal-Sorrento, (ii) the Company shall pay Cal-Sorrento an early termination fee of $108,527, and (iii) the Company shall vacate the premises on or before October 31, 2021. Effective upon the Termination Date and provided that the Company has satisfied all of its obligations pursuant to the Agreement, each of the Company and Cal-Sorrento shall release each other and their respective agents, employees, partners, officers, directors, stockholders and members from all obligations under the Lease.

 

The foregoing description of the Agreement does not purport to be complete and is subject to, and qualified in its entirety, by reference to the full text of the Agreement, a copy of which is attached hereto as Exhibit 10.1.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
10.1   Lease Termination Agreement by and between the Company and Cal-Sorrento, Ltd. dated September 22, 2021
104   Inline XBRL for the cover page of this Current Report on Form 8-K

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GUARDION HEALTH SCIENCES, INC.
Date: September 23, 2021    
  By: /s/ Bret Scholtes
  Name: Bret Scholtes
  Title: Chief Executive Officer

 

 

 

 EX-10.1 2 ex10-1.htm

 

Exhibit 10.1

 

LEASE TERMINATION AGREEMENT

 

This Lease Termination Agreement (the “Agreement”) is entered into on September 22, 2021, by and between Cal-Sorrento, Ltd., a California limited partnership (the “Landlord”) and Guardion Health Sciences, Inc., a Delaware corporation (the “Tenant”, and collectively with Landlord, the “Parties”).

 

RECITALS

 

A. Landlord and Tenant entered into that certain Industrial Lease dated as of October 24, 2012, as amended by that certain First Modification dated as of December 4, 2012, that certain Second Modification dated as of December 12, 2021, that certain Third Modification dated as of November 7, 2013, that certain Fourth Modification dated as of March 23, 2018, and that certain Fifth Modification dated as of March 5, 2020 (as amended, the “Lease”) for that certain real property consisting of approximately 9,605 rentable square feet, commonly known as 15150 Avenue of Science, Suite 200, San Diego, California 92128 (the “Premises”).

 

B. The Parties wish to mutually terminate the Lease and release certain claims and/or liabilities pursuant to the terms of this Agreement.

 

TERMS AND CONDITIONS

 

In consideration of the covenants, representation, and warranties herein contained, and other good and valuable consideration, the receipt of which is acknowledged, the Parties agree as follows:

 

1. LEASE TERMINATION

 

Landlord and Tenant agree that as of October 31, 2021 at 11:59 P.M. Pacific Time (the “Termination Date”), and subject to the agreements, conditions, representations, warranties and indemnities contained in this Agreement, the Lease shall terminate and the Term of the Lease shall expire with the same force and effect as if the Term was, by the provisions thereof, fixed to expire on the Termination Date. Until the Termination Date the Lease shall remain, continue, and be deemed to be, in full force and effect, and Landlord and Tenant shall timely perform each of their respective duties and obligations required thereunder.

 

2. PAYMENT, SURRENDER OF THE PREMISES, AND RELATED PROVISIONS

 

2.1 Payment by Tenant to Landlord

 

As consideration for the early termination of the Lease, on or before the Termination Date (i) Tenant agrees to forfeit to Landlord, the total sum of the security deposit currently held by Landlord, and (ii) Tenant shall pay to Landlord an early termination fee equal to $108,527.00 (collectively, the “Settlement Sum”). The Settlement Sum is intended to be a full settlement between Landlord and Tenant, of Tenant’s monetary and nonmonetary obligations under the Lease, and from and after the Termination Date Tenant shall not be liable for any amounts due or owing under the Lease, including Rent, Base Rent, Additional Rent, or any other monetary obligations under the Lease.

 

-1-
 

 

2.2 Surrender

 

2.2.1 On or before the Termination Date, Tenant shall peaceably and quietly leave the Premises and surrender the Premises to Landlord with all of the improvements, parts and surfaces thereof clean and free of debris, and in the condition required under the Lease, ordinary wear and tear excepted. Tenant shall not remove any demising walls or other improvements made by Tenant during the Term of the Lease. Any personal property of Tenant not removed on or before the Termination Date shall be deemed to have been abandoned by Tenant and may be disposed of or retained by Landlord at Landlord’s discretion. Tenant shall return all keys for the building, common areas and mailbox to Landlord and shall cause to be cancelled any security and/or alarm systems. Subject to the agreements, representations, warranties and indemnities contained in this Agreement, Landlord agrees to accept the surrender of the Lease and the Premises from and after the Termination Date and, effective as of the Termination Date, forever releases and discharges Tenant from all obligations to be observed and performed by Tenant under the Lease after the Termination Date, provided that Tenant has satisfied, performed and fulfilled all of the agreements set forth in this Agreement.

 

2.2.2 The failure by Tenant to timely vacate the Premises pursuant to this Agreement without the express written consent of Landlord shall constitute a material breach of this Agreement and the Lease. In the event Tenant materially breaches its obligations under this Agreement or the Lease prior to vacating the Premises, Tenant shall be liable for the full amount of the Rent and other charges due under the Lease, and all other losses, costs, damages, and expenses incurred by Landlord to the extent resulting from such breach. Provided that Tenant performs all its obligations under this Agreement, Tenant shall not be liable for Rent, Base Rent, Additional Rent, or any other monetary or nonmonetary obligations under the Lease after the Termination Date, and Landlord acknowledges all Tenant’s payment obligations through the Termination Date will have been paid in full, and Tenant shall be liable only for those covenants under the Lease that expressly survive the end of the Term of the Lease and relate to facts and circumstances occurring prior to the Termination Date.

 

3. RELEASE

 

Effective upon the Termination Date, Landlord and Tenant hereby release each other and their agents, employees, partners, officers, directors, shareholders, and members, from all obligations under the Lease; provided, however that the foregoing release shall not apply to any obligations of Tenant or Landlord which by the terms of the Lease are to survive the expiration or termination of the Term of the Lease. Subject to the provisions of the preceding sentence, this Agreement shall fully and finally settle all demands, charges, claims, accounts or causes of action of any nature, including, without limitation, both known and unknown claims and causes of action that arose out of or in connection with the Lease, and it constitutes a mutual release with respect to the Lease. Each of the Parties expressly waives the provisions of any law which would otherwise restrict the extent or nature of this release including, but not limited to, California Civil Code Section 1542 which provides as follows:

 

“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.”

 

     
Tenant’s Initials   Landlord’s Initials

 

-2-
 

 

4. GENERAL PROVISIONS

 

4.1 General. Each Party acknowledges: (i) this Agreement is the resolution of a fully matured set of facts and each Party individually declares and represents it is executing this Agreement in reliance solely on its own judgment, belief, and knowledge of the facts surrounding the transactions described in this Agreement; (ii) this Agreement is made without reliance upon any statement or representation not contained in this Agreement of any other Party, or any representative, agent or attorney of any other Party; (iii) no promise, inducement or agreement not expressed in this Agreement has been made to any Party; and (iv) the recitals, terms and conditions contained in this Agreement are contractual and not mere recitals.

 

4.2 Authority. Each Party represents and warrants it has not assigned its rights in any of its claims against the other Party to any other person or entity, each Party has full authority to bind the Party for which it signs this Agreement, and this Agreement does not violate any provision of any other agreement or document to which either Party is bound.

 

4.3 Control. The provisions of this Agreement and the Lease, as amended, constitute the entire agreement between the Parties and supersede all prior negotiations, proposals, agreements and understandings regarding the subject matter of this Agreement. In the event of any conflict between the terms of this Agreement and the terms of the Lease, the terms of this Agreement shall control. If not defined herein, all capitalized terms used in this document shall have the meaning ascribed to them in the Lease unless the context otherwise requires.

 

4.4 Cooperation. The Parties agree to perform such further acts and to execute and deliver such further documents as may be reasonably necessary or appropriate to carry out the intent or provisions of this Agreement.

 

4.5 Attorney’s Fees. Should either Party initiate any action at law or in equity to enforce or interpret the terms of this Agreement, the prevailing Party shall be entitled to recover its reasonable attorneys’ fees, costs and necessary disbursements against the non-prevailing Party, in addition to any other appropriate relief.

 

4.6 Brokers. Tenant and Landlord each represents and warrants to the other that it has not employed, dealt with or negotiated with any broker, agent or finder in connection with this Agreement and each Party shall indemnify, protect, defend and hold the other Party harmless from and against any and all liability, damage, cost and expense (including, without limitation, reasonable attorneys’ fees and disbursements) arising out of any claim for a fee or commission by any other broker, agent, finder or party in connection with this Agreement as a result of its actions.

 

4.7 Time of Essence. Time is of the essence in the performance of the respective obligations of the Parties as set forth in this Agreement.

 

4.8 Counterparts and Electronic Signatures. This Agreement may be executed in counterparts by the Parties, which counterparts, each of which shall be an original, but all of which shall constitute one and the same instrument. Each Party acknowledges and agrees to permit the use from time to time of telecopy or other electronic signatures in order to expedite the transaction contemplated by this Agreement.

 

4.9 Miscellaneous. This Agreement shall be governed by and construed under the laws of the state in which the Premises are located with jurisdiction for any action thereon the state and county in which the Premises are located. All captions in this Agreement are for reference only and shall not be used in the interpretation of this Agreement or any related document. If any provision of this Agreement shall be determined to be illegal or unenforceable, such determination shall not affect any other provision of this Agreement and all such other provisions shall remain in full force and effect. This Agreement shall be construed without regard to any presumption or other rule requiring construction against the Party causing this Agreement or any part thereof to be drafted. Each of the Parties hereto acknowledge that it has been or has had the opportunity to be represented by counsel of its own choice throughout all of the negotiations which preceded the preparation of this Agreement and in connection with the preparation and execution of this Agreement.

 

[Remainder of Page Intentionally Left Blank]

 

-3-
 

 

IN WITNESS WHEREOF, the Parties hereto are duly authorized and have signed this Agreement as of the date first written above.

 

LANDLORD  
     

CAL-SORRENTO, LTD., a California limited partnership

  
   
Signature: /s/ Samuel Higgins  
Printed Name: Samuel Higgins  
Title: Director of Real Estate  
     
TENANT    
     
GUARDION HEALTH SCIENCES, INC., a Delaware corporation  
     
Signature: /s/ Bret Scholtes  
Printed Name: Bret Scholtes  
Title: President & CEO  

 

-4-

 EX-101.SCH 3 ghsi-20210922.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ghsi-20210922_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ghsi-20210922_pre.xml XBRL PRESENTATION FILE XML 6 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001642375 2021-09-22 2021-09-22 iso4217:USD shares iso4217:USD shares 0001642375 false 8-K 2021-09-22 GUARDION HEALTH SCIENCES, INC. DE 001-38861 44-4428421 2925 Richmond Avenue Suite 1200 Houston TX 77098 (800) 873-5141 false false false false Common Stock, par value $0.001 per share GHSI NASDAQ true false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Sep. 22, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 22, 2021
Entity File Number 001-38861
Entity Registrant Name GUARDION HEALTH SCIENCES, INC.
Entity Central Index Key 0001642375
Entity Tax Identification Number 44-4428421
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2925 Richmond Avenue
Entity Address, Address Line Two Suite 1200
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77098
City Area Code (800)
Local Phone Number 873-5141
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol GHSI
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://guardionhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex10-1.htm ghsi-20210922.xsd ghsi-20210922_lab.xml ghsi-20210922_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "ghsi-20210922_lab.xml" ] }, "presentationLink": { "local": [ "ghsi-20210922_pre.xml" ] }, "schema": { "local": [ "ghsi-20210922.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "GHSI", "nsuri": "http://guardionhealth.com/20210922", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-09-22to2021-09-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://guardionhealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-09-22to2021-09-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001493152-21-023490-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-023490-xbrl.zip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end